Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Date: May 6, 2019
Issue #:
1571Summary:
View the Expanded Table: Some Available Insulins (Source: The Medical Letter)
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research
In Brief: Tegaserod (Zelnorm) Returns
Date: May 6, 2019
Issue #:
1571Summary:
Tegaserod maleate(Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults<65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Constipation irritable bowel syndrome Motegrity prucalopride Resotran Tegaserod Zelnorm Source Type: research
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Date: May 6, 2019
Issue #:
1571Summary:
The FDA has approved siponimod (Mayzent–
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod i s the second
S1P receptor modulator to be approved in the US;
fingolimod(Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients≥10
years old, was the first. The purine antime...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine dimethyl fumarate Fingolimod Gilenya Glatect Glatiramer acetate Glatopa interferod beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy sipo Source Type: research
Brexanolone (Zulresso) for Postpartum Depression
Date: May 6, 2019
Issue #:
1571Summary:
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso– Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication. (Source: The Medical Letter)
Source: The Medical Letter - April 16, 2019 Category: Drugs & Pharmacology Authors: admin Tags: brexanolone Depression SNRIs SSRIS Zulresso Source Type: research
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
Date: April 22, 2019
Issue #:
1570Summary:
Eravacycline (Xerava– Tetraphase), a new synthetic
tetracycline antibiotic, has been approved by the
FDA for IV treatment of complicated intra-abdominal
infections (cIAIs) in adults. Eravacycline is structurally
similar to tigecycline (Tygacil, and generics), a broad-spectrum
tetracycline approved by the FDA for IV
treatment of complicated skin and skin structure
infections, complicated intra-abdominal infections,
and community-acquired pneumonia. A higher rate
of mortality has been reported with use of tigecycline
compared to other an...
Source: The Medical Letter - April 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Ceftriaxone Doripenem eravacycline Ertapenem Escherichia coli Imipenem/cilastatin Invanz meropenem Merrem methicillin-resistant staphylococcus aureus penicillin Piperacillin/tazobactam Primaxin Pseudomonas aerugi Source Type: research
